TBIO
NASDAQTelesis Bio Inc.
Price$3.14+0.00 (+0.00%)
2025-06-252025-09-26
Latest news
25 items- PRTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisNew technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e
- PRTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisTelesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,
- SECSEC Form 15-12G filed by Telesis Bio Inc.15-12G - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form EFFECT filed by Telesis Bio Inc.EFFECT - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form EFFECT filed by Telesis Bio Inc.EFFECT - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form POS AM filed by Telesis Bio Inc.POS AM - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form POS AM filed by Telesis Bio Inc.POS AM - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form S-8 POS filed by Telesis Bio Inc.S-8 POS - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form S-8 POS filed by Telesis Bio Inc.S-8 POS - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form S-8 POS filed by Telesis Bio Inc.S-8 POS - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form 8-K filed by Telesis Bio Inc.8-K - Telesis Bio Inc. (0001850079) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Telesis Bio Inc.SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
- SECSEC Form 10-Q filed by Telesis Bio Inc.10-Q - Telesis Bio Inc. (0001850079) (Filer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Telesis Bio Inc.SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by Telesis Bio Inc.SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
- SECTelesis Bio Inc. filed SEC Form 8-K: Leadership Update8-K - Telesis Bio Inc. (0001850079) (Filer)
- PRTelesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA SynthesisSAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson
- SECSEC Form 25 filed by Telesis Bio Inc.25 - Telesis Bio Inc. (0001850079) (Filer)
- SECTelesis Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Telesis Bio Inc. (0001850079) (Filer)
- PRTelesis Bio Plans to Delist its Securities from The Nasdaq Stock MarketSAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO) ("Telesis" or the "Company"), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.001 per share (the "Common Stock") and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Telesis intends to file a Form 25 with the Securities and Exchange Commission (the "SEC")
- SECTelesis Bio Inc. filed SEC Form 8-K: Leadership Update8-K - Telesis Bio Inc. (0001850079) (Filer)
- SECTelesis Bio Inc. filed SEC Form 8-K: Other Events8-K - Telesis Bio Inc. (0001850079) (Filer)
- SECTelesis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Telesis Bio Inc. (0001850079) (Filer)
- SECSEC Form 10-Q filed by Telesis Bio Inc.10-Q - Telesis Bio Inc. (0001850079) (Filer)
- SECTelesis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Telesis Bio Inc. (0001850079) (Filer)
TBIO FAQ
7 questionsWhat does Telesis Bio Inc. do?
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in...Where does TBIO stock trade?
Telesis Bio Inc. (TBIO) is listed on NASDAQ.What sector and industry is TBIO in?
Telesis Bio Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Telesis Bio Inc. go public?
Telesis Bio Inc. (TBIO) completed its IPO in 2021.What are analysts saying about TBIO?
Telesis Bio Inc. has had 4 recent analyst actions on file. The most recent action was from Roth Capital: Neutral with a $3800.00 price target on 2021-08-04. Recent price targets range from $3800.00 to $4500.00.What companies are similar to TBIO?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare TBIO side-by-side with any of them on Quantisnow.How can I track TBIO on Quantisnow?
Quantisnow aggregates Telesis Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TBIO to receive live email and push alerts on every new disclosure.